Advanced Filters
noise

chemotherapy Clinical Trials

A listing of chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,618 clinical trials

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.

18 years of age All Phase 1
Y Yi-Ting Lin

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Background: While third-generation EGFR tyrosine kinase inhibitors (TKI) like aumolertinib have significantly improved outcomes for patients with advanced lung adenocarcinoma, those harboring the L858R mutation still experience inferior prognosis compared to those with exon 19 deletions. Recent evidence suggests that combining TKIs with chemotherapy improves progression-free survival (PFS), but universal …

18 years of age All Phase 2
D Dominique GENRE, MD

Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy

The present project aims at identifying robust candidates for drug resistance in BC patients eligible for NAC. Its originality lies upon the combination of three different and complementary prospective approaches: from the molecular analyses of biopsies sampled before and after NAC, from in vitro BC Patient-Derived Organoids (PDO) mimicking patient's …

18 years of age Female Phase N/A
H Huai Liu, MD

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.

18 - 75 years of age All Phase 2
S Shira Dinner, MD

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

18 years of age All Phase 2
V Vladislav Sarzhevskiy, MD, PhD

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

18 - 50 years of age All Phase 3
K Kamaljit Singh

The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment

A cross-sectional retrospective study of a sample of 20 women who completed single agent or multi agent chemotherapy: between 6 weeks and 24 months post treatment involving a semi structured telephone interview. A patient sample of 20 is proposed for the study. These are all the patients who meet the …

16 - 55 years of age Female Phase N/A
l lin yang

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are: Does ivonescimab plus chemotherapy raise the objective response …

18 years of age All Phase 2
S Shaoxing Zhu, MD

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder preservation, in patients with HER2-positive muscle-invasive bladder cancer (MIBC) staged cT2-4aN0-1M0.

18 - 85 years of age All Phase 2
Y Yuan Ying, ph.D & MD

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer

18 - 75 years of age All Phase 2

Simplify language using AI